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Background: Cerium dioxide nanoparticles (nanoceria) are increasingly being used in a variety 
of products as catalysts, coatings, and polishing agents. Furthermore, their antioxidant properties 
make nanoceria potential candidates for biomedical applications. To predict and avoid toxic-
ity, information about their biokinetics is essential. A useful tool to explore such associations 
between exposure and internal target dose is physiologically based pharmacokinetic (PBPK) 
modeling. The aim of this study was to test the appropriateness of our previously published 
PBPK model developed for intravenous (IV) administration when applied to various sizes of 
nanoceria and to exposure routes relevant for humans. 
Methods: Experimental biokinetic data on nanoceria (obtained from various exposure routes, 
sizes, coatings, doses, and tissues sampled) in rats were collected from the literature and also 
obtained from the researchers. The PBPK model was first calibrated and validated against IV 
data for 30 nm citrate coated ceria and then recalibrated for 5 nm ceria. Finally, the model was 
modified and tested against inhalation, intratracheal (IT) instillation, and oral nanoceria data.
Results: The PBPK model adequately described nanoceria time courses in various tissues for 
5 nm ceria given IV. The time courses of 30 nm ceria were reasonably well predicted for liver 
and spleen, whereas the biokinetics in other tissues were not well captured. For the inhalation, 
IT instillation, and oral exposure routes, re-optimization was difficult due to low absorption and, 
hence, low and variable nanoceria tissue levels. Moreover, the nanoceria properties and exposure 
conditions varied widely among the inhalation, IT instillation, and oral studies, making it difficult 
to assess the importance of different factors. 
Conclusion: Overall, our modeling efforts suggest that nanoceria biokinetics depend largely 
on the exposure route and dose.
Keywords: biodistribution, cerium dioxide, inhalation, instillation, intravenous, oral
Introduction
The most common commercial form of cerium is cerium dioxide, also known as ceric 
oxide or ceria. Nanoscale forms of ceria (nanoceria) are used in a variety of products 
as catalysts, fuel additives and cells, polishing agents, and coatings.1–4 The ability of 
nanoceria to react catalytically with reactive oxygen species has made it interesting for 
use in biomedical applications, such as therapeutic agents in the treatment of diseases 
related to oxidative stress, including obesity, wound healing, retinal degeneration, and 
Alzheimer’s disease.5–10
Increased consumer and worker exposure to nanoceria combined with sparse avail-
ability and conflicting toxicological information have raised concerns for health effects 
in the human population.3,11,12 Systemic uptake of nanoceria is quite low (typically ,1% 
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for inhalation and even less for oral exposure), nevertheless 
bioaccumulation may occur due to slow dissolution and 
excretion.13–15 Acute toxicity is considered to be low; how-
ever, long-term inhalation and oral studies show that toxicity 
may occur in tissues distant to the uptake site, suggesting 
systemic uptake is of importance.3,16–18 For example, high 
oral doses of nanoceria caused severe liver, spleen, and brain 
damage in rats.17 The results of safe-by-design concepts used 
in an attempt to reduce toxicity are promising. For example, 
the lung inflammatory response to intratracheal (IT) instil-
lation of nanoceria coated with amorphous silica was lower 
compared to uncoated nanoceria.19
To better predict the toxic effects and toxic mechanisms 
of nanomaterials, understanding their biokinetics is crucial. 
Biokinetics can be elucidated by physiologically based phar-
macokinetic (PBPK) modeling. The PBPK model converts 
physiological and anatomical properties to mass balance equa-
tions and describes the time-dependent fate of substances in the 
body, linking exposure to the internal (target) dose.20,21 By use 
of experimental data from biodistribution studies, the model 
can be developed, calibrated, refined, and validated.22,23 There 
is a limited number of PBPK models for nanoparticles, and to 
our knowledge, so far, no model for intravenous (IV) exposure 
has been calibrated and validated for nanoceria.24–51
Modeling efforts have demonstrated that there are many 
challenges to the development of models for nanoparticles.22,23,52 
The biological activity of nanoparticles differs from their 
solute and larger forms.53–59 However, these factors are not 
well characterized in quantitative terms and thus not readily 
implemented in PBPK models. One limiting factor in the 
development of PBPK models for nanoparticles is the avail-
ability of rich in vivo data, with well-characterized properties 
of nanoparticles, multiple doses, multiple tissues, and multiple 
sampling times. The IV route is important as bioavailability is 
100%; hence, IV studies serve as a reference when studying 
biokinetics after exposure via other routes. In addition, IV dos-
ing is the likely choice if nanoceria are to be used as therapeutic 
agents, since bioavailability via other routes is low.
In this study, we applied our previously developed PBPK 
model for different nanoparticles given IV to rats to nano-
ceria of different sizes and coatings.52 We further modified 
the model to account for inhalation, IT instillation, and oral 
exposures to nanoceria.
Materials and methods
Data source
Experimental data on the biodistribution of nanoceria admin-
istered to rats were collected from the literature or received 
directly from authors. Data published only in graphs were 
extracted using WebPlotDigitizer version 2.6. Only studies 
where dose and tissue levels of nanoceria could be converted 
to mass or concentration were included. Data were converted 
to cerium dioxide concentration. We found eight publications 
of biodistribution studies with IV exposure, reporting 21 data 
sets with different nanoceria sizes (3, 5, 15, 30, 40, and 
55 nm), coatings (uncoated, citrate, or EDTA-citrate), doses 
(between 6 and 750 mg/kg), and dosing methods (bolus and 
infusion).15,60–66 Inhalation or IT instillation were addressed in 
seven publications, which included 14 data sets.13,14,18,49,53,67,68 
Oral uptake was described in six publications, which included 
12 data sets.14,17,53,67,69,70 The experimental studies are sum-
marized in Tables 1–4.
Due to the limited and scattered nature of these biodistri-
bution studies, assigning the data to calibration and validation 
sets could not be randomized. Instead, the data sets for 
calibration were chosen based on the following inclusion 
Table 1 summary of biodistribution studies with IV dosed sprague Dawley rats which are used to calibrate and validate the PBPK 
model for 5 nm ceria 
Exposure Size 
(nm)
Coating Dose 
(mg/kg)
Post-exposure sampling times Tissues sampled Reference
Calibration
Infusion (1 h) 5a citrate 85 1 h, 20 h, 30 d Bl, Br, li, sp 60
Infusion (1 h) 5a citrate 11 30 d Bl, BM, Bo, Br, he, Ki, li, lN, lu, Mu, sp, Th 61
Validation
Infusion (1 h) 5a citrate 85 0.17 h, 0.5 h, 0.75 h, 1 h, 20 h, 30 d Bl 65 
Infusion (1 h) 5a citrate 85 1 h, 20 h Bl, Br, li, sp 63
Infusion (1 h) 5a citrate 55 30 d ag, Bl, BM, Bo, Br, Fa, he, Ki, li, lN, lu, 
Mu, sp, Th
61
Bolus 3b citrate/eDTa 10 0.08 h, 0.33 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, 24 h Bl 62
Notes: aMeasured by TeM. bMeasured by Dls and TeM.
Abbreviations: ag, adrenal gland; Bl, blood; BM, bone marrow; Bo, bone; Br, brain; d, days; Dls, dynamic light scattering; Fa, fat; h, hours; he, heart; IV, intravenous; Ki, kidney; 
li, liver; lN, lymph node; lu, lung; MMaD, median aerodynamic diameter; Mu, muscle; PBPK, physiologically based pharmacokinetic; sp, spleen; Th, thymus; TeM, transmission 
electron microscopy.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
09
-J
an
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2633
PBPK modeling of nanoceria suggests dose- and route-dependent biokinetics
criteria: 1) the total recovered mass in analyzed tissues should 
be at least 25% of the injected dose, and 2) nanoceria levels 
should be reported for more than four internal tissues and 
include at least three time points. The remaining data sets 
were used for validation.
comparison of biodistribution data  
for the non-IV exposure routes
The collected data sets for biodistribution after inhalation 
exposure, IT instillation, and oral administration varied in study 
design (dose, dose frequency, sampling frequency, and collected 
tissues), and the nanoceria used had different properties.
Only the administered dose was given in these data 
sets, the systemically absorbed fraction being unknown. 
However, liver is a major target tissue for nanoceria and the 
most frequently sampled internal organ in the data sets. The 
nanoceria mass in liver was therefore used as a surrogate for 
systemic absorption; this allowed for comparison among the 
different studies. Nanoceria translocation from the lung and 
gastrointestinal tract was thus calculated by dividing the mass 
in liver with the IT and orally administered dose, respectively. 
For inhalation, the nanoceria mass in lung was used instead 
of administered dose.
Reported delivered dose and internal organ concentra-
tions differed substantially among exposure routes. To allow 
for comparisons of the biodistribution among data sets and 
exposure routes, the experimental data were first normalized 
by dividing the nanoceria concentration in each tissue by the 
average concentration in the liver, here called the tissue:liver 
concentration ratio.
PBPK model structure
Studies of nanoceria given IV to rats show, as do similar 
studies with other nanoparticles, that nanoceria are captured 
by phagocytic cells (PCs) in tissues belonging to the mono-
nuclear phagocyte system (MPS), including liver, spleen, and 
bone marrow.14,53,61,63 Once distributed to the MPS, nanoceria 
reside there for a long time.14,15 We based the PBPK model 
on the one previously developed by Carlander et al.52 The 
model consists of 10 compartments: arterial blood, venous 
blood, liver, spleen, lung, kidney, heart, brain, bone marrow, 
and other tissues (Figure 1). Each compartment is divided 
Table 2 summary of biodistribution studies with IV dosed rats which are used to calibrate and validate PBPK model for 30 nm ceria
Exposure Sizea 
(nm)
Coating Dose 
(mg/kg)
Post-exposure 
sampling times
Tissues sampled Rat 
strain
Excreta 
sampled
Reference
Calibration
Infusion (1 h) 31 citrate 87 24 h, 7 d, 30 d, 90 d ag, Bl, BM, Br, cr, csF, Fe, he, Int, 
Ki, li, lu, Mu, Pe, sc, sk, sp, Te, Th 
s. Dawley U+F 15
Validation
Infusion (0.5, 2.5, 
or 7.5 h) 
30 citrate 50
250
750
1 h, 20 h Bl, Br, li, sp Fisher – 66
Infusion (1 h) 31 citrate 85 0.17 h, 0.5 h, 0.75 h, 1 h, 
20 h, 24 h, 7 d, 30 d, 90 d
Bl s. Dawley – 65
Infusion (1 h) 31 citrate 85 1 h, 20 h, 30 d Bl, Br, li, sp s. Dawley – 60
Infusion (1 h) 31 citrate 6 1 h, 30 d, 90 d ag, Bl, BM, Br, Fa, he, Ki, li, lN, 
lu, Mu, sk, sp, Th
s. Dawley 61
Bolus 28
29
Uncoated
silica
1
1
2 h, 2 d Bl, BM, Br, ce, Fe, he, Ki, li, lIn, 
lu, Mu, Pl, rBc, sIn, sk, sp, st, Te
Wistar – 53
Notes: aMeasured by TeM.
Abbreviations: AG, adrenal gland; Bl, blood; BM, bone marrow; Br, brain; Ce, cecum; Cr, cranium; CSF, cerebrospinal fluid; d, days; F, feces; Fa, fat; Fe, femur; h, hours; He, 
heart; Int, intestine; IV, intravenous; Ki, kidney; li, liver; lIn, large intestine; lN, lymph node; lu, lung; Mu, muscle; PBPK, physiologically based pharmacokinetic; Pe, pelvis; Pl, 
plasma; rBc, red blood cells; sc, spinal column; sIn, small intestine; s. Dawley, sprague Dawley; sk, skin; sp, spleen; st, stomach; Te, testis; Th, thymus; TeM, transmission 
electron microscopy; U, urine.
Table 3 summary of biodistribution studies with sprague Dawley rats IV dosed with 15 and 55 nm ceria
Exposure Sizea 
(nm)
Coating Dose 
(mg/kg)
Post-exposure sampling times Tissues 
sampled
Reference
Infusion (1 h) 15
55
citrate
citrate
70
50
0.17 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 20 h
0.17 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 20 h
Bl
Bl
65
Infusion (1 h) 15
55
citrate
citrate
70, 345
50, 100
1 hb, 30 dc
1 hd, 20 he
Bl, Br, li, sp
Bl, Br, li, sp
60
Notes: aMeasured by TeM. bsampling time for 345 mg/kg. csampling time for 70 mg/kg. dsampling time for 100 mg/kg. esampling time for 50 and 100 mg/kg.
Abbreviations: Bl, blood; Br, brain; d, day; h, hour; IV, intravenous; li, liver; sp, spleen; TeM, transmission electron microscopy.
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Table 4 summary of inhalation, IT instillation, and oral biodistribution studies with nanoceria in rats
Exposure Size Coating Dose/exposure 
concentration, 
dose/exposure 
schedule
Post-exposure 
sampling times
Tissues sampled Excreta 
sampled
Rat 
strain 
Reference
Inhalation TeM 40 nm 
MMaD 1.17 µm 
Uncoated 20 mg/m3, 6 h/d, 
1, 11 and 19 d 
exposures, nose only
,1 h, 3 da Bl, Br, epi, Ki, li, 
lu, sp, Te
– Wistar 13
 TeM 5–10 nm 
MMaD 1.02 µm 
Uncoated 11 mg/m3, 6 h/d,  
and 20 d exposures, 
nose only
,1 h, 2 db Bl, Br, epi, Ki, li, 
lu, sp, Te
– Wistar 13
 TeM 40 nm 
MMaD 1.17 µm 
Uncoated 25 mg/m3, 6 h/d, 5 
d/w, 4 w, whole body
24 h,c 2 d,d 3 d,e 9 d,d 
35 d,c 65 d,e 129 dc
li, lN, lu – Wistar 18
TEM 2–3 nm Uncoated 
(pristine) 
0.2, 0.6 mg/m3, 
4 or 6 h/d, 1 d, 
nose only
0.25 h, 24 h, 7 d Bl, Br, GIT, He, 
Ki, Li, Lu, Ofb, 
Sp
U+F S. 
Dawley
49
Uncoated 
(aged)
0.4, 0.5 mg/m3, 
4 h/d, 1 d, nose only
0.25 h, 24 h, 7 d Bl, Br, GIT, He, 
Ki, Li, Lu, Ofb, Sp
U+F S. 
Dawley
49
IT instillation TEM 7 nm, 
DLS 13 nm
Uncoated 0.2 mg 6 h, 1 d, 7 d, 28 d Bl, Br, Fe, He, 
Int, Ki, Li, Lu, 
Mu, Sp, St, Te
U+F Wistar 67
 TeM 10 nm Not reported 1, 3.5, 7 mg/kg 28 d li – s. Dawley 68
 TeM 40 nm 
(NM-212)
Uncoated 1 mg/kg 0.08 h,f 24 h,g 2 d,f 
3 d,g 7 d,g,h 10 d,g 
14 d,g 21 d,g 28 di
Bl, BM, Bo, Br, ce, 
he, Ki, li, lIn, lu, 
Mu, Pl, rBc, sIn, 
sk, sp, st, Te
U+F Wistar 14
 TeM 33 nm, 
Dls 136 nm
Uncoated 1 mg/kg 0.08 h,f 24 h,g 2 d,f 
3 d,g 7 d,f,g 10 d,g 
14 d,g 21 d,g 28 dg,h
BM, Bo, Br, ce, 
he, Ki, li, lIn, lu, 
Mu, Pl, rBc, sIn, 
sk, sp, st, Te
U+F Wistar 53
 TeM 33 nm, 
Dls 208 nm
silica 1 mg/kg 0.08 h,f 24 h,g 2 d,f 
3 d,g 7 d,f,g 10 d,g 
14 d,g 21 d,g 28 dg,h
BM, Bo, Br, ce, 
he, Ki, li, lIn, lu, 
Mu, Pl, rBc, sIn, 
sk, sp, st, Te
U+F Wistar 53
Oral TEM 7 nm, 
DLS 13 nm
Uncoated 1 mg (~5 mg/kg) 1 d, 7 d, 28 d Bl, Br, Fe, He, 
Int, Ki, Li, Lu, 
Mu, Sp, St, Te
U+F Wistar 67
SEM 30 nm Uncoated 100, 5,000 mg/kg 24 h, 7 d, 14 d Br, Ki, Li, Lu, 
Sp, Te
– S. 
Dawley
69
 TEM 23 nm, 
DLS 190 nm
Uncoated 100, 500, 
1,000 mg/kg
4 h, 24 h, 2 d, 3 d Bl, Br, He, Ki, 
Li, Sp
U+F Wistar 70
 TeM 24 nm,
Dls 191 nm
Not reported, 
99.5% pure
30, 300, 600 mg/kg 
(daily dosing for 28 d)
1 d (after last dose) Bl, Br, he, Ki, 
li, sp
U+F Wistar 17
 TeM 40 nm
(NM-212) 
Uncoated 5 mg/kg 0.08 h,h 24 h,g 3 d,g 
7 dg,h
Bl, BM, Bo, Br, ce, 
he, Ki, li, lIn, lu, 
Mu, Pl, rBc, sIn, 
sk, sp, st, Te
U+F Wistar 14
TeM 33 nm, 
Dls 136 nm
Uncoated 5 mg/kg 0.08 h,j 24 h,g 3 d,g 
7 dg,h
BM, Bo, Br, ce, 
he, Ki, li, lIn, lu, 
Mu, Pl, rBc, sIn, 
sk, sp, st, Te
U+F Wistar 53
TeM 33 nm, 
Dls 208 nm
silica 5 mg/kg 0.08 h,j 24 h,g 3 d,g 
7 dg,h
BM, Bo, Br, ce, 
he, Ki, li, lIn, lu, 
Mu, Pl, rBc, sIn, 
sk, sp, st, Te
U+F Wistar 53
Notes: Studies in bold fulfilled the inclusion criteria for calibration. aOnly after 19 d exposures. bOnly after 20 d exposures. cTime point after start of first administration. Only lung 
sampled. dTime point after start of first administration. Lung and lymph node sampled. eTime point after start of first administration. Liver, lung, and lymph node sampled. fOnly 
concentration in lung and “extra pulmonary” tissues (lumping of all internal tissues) were reported for these post-exposure sampling times. gOnly samples in urine and feces. hsamples from 
all tissues. iOnly concentrations in Bl, BM, Bo, Br, gIT, he, Ki, li, Mu, sk, sp, Te were reported for these post-exposure sampling times. jOnly tissues samples from Bo, lu, Mu, sIn, sk.
Abbreviations: Bl, blood; BM, bone marrow; Bo, bone; Br, brain; ce, cecum; d, days; Dls, dynamic light scattering; epi, epididymis; F, feces; Fe, femur; gIT, gastrointestinal 
tract; h, hours; he, heart; Int, intestine; IT, intratracheal instillation; Ki, kidney; li, liver; lIn, large intestine; lN, lymph node; lu, lung; MMaD, median aerodynamic diameter; 
Mu, muscle; Ofb, olfactory bulb; rBc, red blood cells; s. Dawley, sprague Dawley; seM, scanning electron microscopy; sIn, small intestine; sk, skin; sp, spleen; st, stomach; 
Te, testis; TeM, transmission electron microscopy; U, urine.
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into three sub compartments: 1) blood in tissue, 2) tissue, and 
3) PCs in the tissue, with venous and arterial blood described 
by two subcompartments: blood and PCs.
The PCs are described by a particle-dependent uptake 
rate constant (K
sab0
 for spleen and K
ab0
 for all other tissues), 
an exocytosis rate constant (K
de
), and a maximum uptake 
capacity (M
cap
). With one exception (K
sab0
), all PCs are 
assumed to have the same properties (ie, same K
ab0
 and M
cap
), 
and only their numbers (a particle-independent parameter) 
differ among compartments. The model includes flow and 
diffusion-limited processes from blood to tissues described 
by three permeability coefficients (X
fast
 for liver, spleen, and 
bone marrow; X
brain
 for the blood–brain barrier; and X
rest
 for 
other tissues). Partitioning between blood and other tissues 
is expressed by a partition coefficient (P). Excretion occurs 
from the liver and kidney and is accounted for by clearance 
rate constants (CL
f
 and CL
u
, respectively).
Systemic uptake after inhalation, IT instillation, and oral 
exposure is addressed by adding a first-order absorption com-
partment to the PBPK model. The absorption rate constant 
(a route- and particle-dependent parameter) was obtained 
by best fit to each data set. Clearances from the lungs via 
the mucociliary escalator and from the gastrointestinal tract 
to feces are also described by first-order kinetics and were 
obtained by best fit to the respective data sets. Dissolution 
of nanoceria has been reported but experimental data useful 
for modeling are lacking so far.71 For this reason, dissolution 
is not included in the model.
Model calibration
The model was parameterized by best fit against experi-
mental tissue concentrations of nanoceria given IV to rats. 
All physiological (nanoparticle independent) parameters 
of the model were kept the same as previously reported by 
Figure 1 schematic illustration of the physiologically based pharmacokinetic (PBPK) model. 
Notes: Black arrows indicate transport of nanoceria between subcompartments, blue and red arrows represent systemic circulation, green arrows indicate uptake into 
the circulatory system, and dashed arrows indicate excretion. The blue area is venous blood, and the red area is arterial blood. green boxes correspond to exposure via 
inhalation/intratracheal instillation, and intravenous and oral administration. The grey box represents tissue. White boxes with the text Pc symbolize phagocytic cells in tissue. 
Orange boxes indicate clearance of nanoceria to mucus, urine, and feces.
Intravenous
dose
Feces
Urine
A
rterial blood
Oral dose
PC
Liver
PC
Spleen
PC
Other tissues
PC
Kidney
PC
Heart
PC
Brain
PC
Bone marrow
PC
Lung
PC
Ve
no
us
 b
lo
od
PC
Mucus
clearance
Inhalation
instillation
dose
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
09
-J
an
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2636
carlander et al
Carlander et al (Table S1), except for scaling to body weight 
in the individual experiments.52 The fitted (nanoparticle-
dependent) parameters were CL
f
, CL
u
, k
ab0
, k
sab0
, k
de
, P, M
cap
, 
X
brain
, X
rest
, and X
fast
.
As size has been reported to influence the biokinetics 
of nanoparticles, the model was fitted against 5 and 30 nm 
experimental IV data separately.15,60,61 Excretion data for 
nanoceria have only been reported for 30 nm particles, 
where the amount of nanoceria recovered in feces and 
urine was reported to be ,0.5% and 0.01% of the dose, 
respectively.14,15 The clearance rate constants for urine and 
feces were estimated during the calibration of the PBPK 
model for 30 nm ceria and next used as fixed values in the 
calibration of 5 nm ceria.
For calibration of the model for 5 nm ceria, we used two 
sets of experimental data reported by Yokel et al (85 mg/kg, 
1 h infusion, and 11 mg/kg, 1 h infusion) (Table 1).60,61 Both 
the data sets cover three sampling times (1 h, 20 h, and 30 d 
post-infusion) and report concentrations for all tissues defined 
in our PBPK model. Calibration of the model for 30 nm ceria 
was carried out using the richest available data set (number of 
tissues collected, number of sampling times, and time span) 
(87 mg/kg, 1 h infusion) (Table 2).15 This data set covers four 
sampling times and cerium concentrations in all tissues in 
our model as well as in urine and feces.
Regarding inhalation, IT instillation, and oral exposure 
studies, only one study for inhalation, one for IT instillation, 
and three for the oral route fulfilled the calibration criteria 
(Table 4). The studies that did not fulfill the calibration 
criteria were used to calculate liver:dose ratios for com-
parison among exposure routes. The calibration involved 
fitting each data set by changing nanoparticle-dependent 
parameters, the absorption rate constant (all three routes), 
the mucociliary clearance rate constant (inhalation and IT 
instillation), and the gastrointestinal clearance rate constant 
(oral route).
In the calibration using inhalation, IT instillation, and 
ingestion data, we departed from the initial calibration with 
5 and 30 nm IV data and added two route-dependent rate 
constants, for absorption (all three routes) and clearance 
(mucociliary for inhalation and IT instillation, gastrointes-
tinal for the oral route). We first tried to achieve calibration 
by fitting all nanoparticle-dependent parameters. However, 
no results could be obtained due to the high number of 
parameters combined with relatively few data points and 
widely disparate experimental data. In a second attempt, we 
considered the parameters from the IV calibration and fitted 
the route-dependent parameters only.
Model validation
The model was validated with additional independent biodis-
tribution studies that used 5 and 30 nm, or similarly sized, 
ceria. In addition, as proposed by the WHO, the validation 
was considered adequate if the simulated values were within 
a factor of two of the measured mean values.21
Four IV data sets were used for the validation of our 
PBPK model for 5 nm ceria (Table 1),61–63,65 and for the 30 nm 
PBPK model, five IV data sets (Table 2)53,60,61,65 were used. 
The data sets cover doses of 1–750 mg/kg, infusion dura-
tions between 0 and 7.5 h, and post-dosing sampling up to 
90 days. The nanoceria were either uncoated or coated with 
citrate, citrate/EDTA, or silica.
sensitivity analysis
Local sensitivity analyses were carried out to identify the 
most influential model parameters. Normalized sensitivity 
coefficients were calculated by dividing the percent change in 
the area under the concentration–time curve in tissues (blood, 
liver, spleen, brain, and PCs) by the percent change in differ-
ent model parameters, as described by Carlander et al.52
Modeling software and algorithms
Computer simulations were carried out with acslX Libero™ 
version 3.0.2.1 using the Gear algorithm or Berkeley 
Madonna™ version 8.3.18 using the Runge-Kutta (4th-order) 
method. AcslX Libero with the Nedler Mead method was 
used for optimization.
The overall goodness of fit between the simulated and 
experimental data was evaluated using linear regression 
in GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, 
CA, USA).
Results
IV exposure – 5 nm ceria
As shown in Figure 2, the PBPK model adequately describes 
the measured concentration of 5 nm ceria in liver, brain, and 
bone marrow (less than twofold differences) and in blood, 
spleen, lung, kidney, and heart reasonably well (less than 
10-fold difference). Furthermore, the simulated values cor-
relate well with the experimental data reported by Yokel et al 
in 2013 (Figure S1A) and correlate reasonably well with 
those reported by Yokel et al in 2014 (Figure S1B).60,61 The 
overall coefficient of determination (R2) for both the data 
sets is 0.91 (Figure 2).
Four independent data sets were used to validate the 
PBPK model for 5 nm ceria. In three of the data sets, the 
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properties were identical to those in the calibration data 
sets, whereas in the fourth, the size (3 nm instead of 5 nm) 
and coating (citrate/EDTA instead of citrate only) differed 
slightly. The simulations indicate differences in time courses 
in blood between these two types of nanoceria. Thus, for 
the 5 nm ceria, the model predicts well the most observed 
concentrations in tissues, whereas for the 3 nm ceria, it 
underpredicts the concentration in blood at every time 
point, suggesting dependence on size and coating (Figures 3 
and S2). This suggests that EDTA/citrate coating prolongs 
the circulation time in blood, a conclusion also drawn by 
Heckman et al.62
The sensitivity analysis showed that the concentrations in 
the different compartments are influenced by physiological- 
and nanoparticle-dependent parameters and dose and are 
time dependent (Figure 4 and Tables S2–S7, sensitivity 
coefficients are shown for two time points only for each dose 
set). The most influential nanoparticle-dependent parameters 
are k
ab0
, k
sab0
, M
cap
, P, X
brain
, and X
rest
, as described further 
in the “Discussion” section (Figure 4). As a consequence 
of nonlinear kinetics in the model (saturation of PCs), the 
concentration in tissues does not increase in proportion to 
dose as dose increases from 11 to 85 mg/kg. This nonlinearity 
is seen as sensitivity coefficients that change with dose 
(Figure 5). For most tissues, the sensitivity coefficients gener-
ally increase with dose rate. For liver, the trend is opposite 
with decreasing sensitivity coefficients for all examined 
nanoparticles (Figure 5C).
IV exposure – 30 nm ceria
The model describes the experimental data for 30 nm ceria 
fairly well with a reasonable correlation between simulated 
and measured values (R2 =0.82, Figure 6). In particular, 
the time courses in liver and bone marrow are adequately 
captured with less than twofold difference between measured 
and simulated values. However, the increases in concentra-
tion observed after 90 days compared to 30 days after dosing 
in various tissues (blood, brain, heart, lung, and spleen) are 
not well captured, that is, the model overestimates at 30 days 
but underestimates at 90 days (Figure 6).
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Figure 2 Physiologically based pharmacokinetic (PBPK) model calibration of 5 nm ceria administered intravenously to rats. 
Notes: (A and B) simulated (solid curves) and experimentally observed concentrations (circles) in tissues of rats at various time points, following 1 h intravenous (IV) 
infusion of 85 mg/kg body weight. Data from Yokel et al.60 (C) simulated and experimentally observed concentrations in tissues of rats, 30 days after a 1 h infusion of 11 
mg/kg body weight. error bars represent standard deviation for experimental observed data. Data from Yokel et al.61 (D) comparison of logs of simulated and observed mean 
concentration in tissues. The line of unity (solid) represents a perfect match, and the regression line (R2, dashed) describes the outcome. Data from Yokel et al.60,61
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Figure 3 Validation of the physiologically based pharmacokinetic (PBPK) model against independent data sets with 5 nm ceria administered intravenously into rats. 
Notes: (A and B) simulated (solid curves) and observed (symbols) time courses of the concentration of 5 nm ceria in different tissues following intravenous infusion in rats 
from different studies (A, data from Dan et al,65 B, data from hardas et al63). (C) simulated (grey columns) and observed (black columns) concentrations of 5 nm ceria in 
different tissues following intravenous infusion in rats. Data from Yokel et al.61 (D) comparison of logs of simulated and observed mean concentration in different tissues. The 
line of unity (solid) represents a perfect match, and the regression line (R2, dashed) describes the outcome. Data from Yokel et al,61 Dan et al,65 and hardas et al.63
As expected, the nanoparticle-dependent parameters 
obtained for 30 nm ceria deviate from those obtained for 5 nm 
ceria (Table 5). Four of the fitted nanoparticle-dependent 
parameters (k
ab0
, k
de
, M
cap
, and X
fast
) are similar, that is, within 
a factor of 2. The remaining four parameters differ more, thus, 
the uptake rate constant for PCs in spleen (k
sab0
) is 22-fold 
lower; the partition coefficient between blood and tissues (P) 
is fivefold lower; the coefficient of permeability from blood 
to lung, kidney, heart, and carcass (X
rest
) is eightfold lower; 
and the coefficient of permeability from blood to brain (X
brain
) 
is 242-fold lower for the 30 nm compared to 5 nm ceria.
The validation of the model against independent data 
from 30 nm ceria show poor predictions for most tissues 
(Figures 7 and S3–S10). The predictions are somewhat better 
for liver and spleen, compared to other tissues. Half of the 
predictions are within twofold of the experimental values.
The sensitivity analysis for the 30 nm ceria shows similar 
pattern as for 5 nm but with fewer highly sensitive param-
eters (Figure 4 and Tables S2–S7). The most influential 
nanoparticle-dependent parameters are k
ab0
, k
sab0
, M
cap
, P, and 
X
rest
. A change in maximum uptake capacity of PCs has less 
influence on the sensitivity coefficient in the 30 nm model 
than in the 5 nm model (Figure 4). Similar to the 5 nm PBPK 
model, the 30 nm PBPK model suggests nonlinear (saturated) 
biokinetics for nanoceria.
IV exposure – other sizes
It was not possible to calibrate the model for 15 and 55 nm 
ceria due to the limited and scattered experimental data. We 
therefore compared these two data sets to predictions based 
on the calibrations obtained with the 5 and 30 nm data. For 
both the data sets, the 5 nm provides better predictions than 
the 30 nm calibration. A closer look at the simulations reveals 
that the predictions for liver and spleen are reasonable, 
whereas those for blood and brain are poorer. For the 15 nm 
ceria, all liver and spleen values are within twofold differ-
ence, whereas for the 55 nm ceria, 80% are within fivefold 
and none differ more than 10-fold (Figures S11 and S12).
Inhalation, IT instillation, and oral exposure
The compilation of data from inhalation, IT instillation, and 
oral biodistribution studies underscores that the systemic 
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PBPK modeling of nanoceria suggests dose- and route-dependent biokinetics
uptake via these routes is limited, in agreement with conclu-
sions previously reached by others (Figure 8).16 Less than 
1% (on mass basis) of the administered dose was distributed 
from lung to liver, and after oral gavage, the uptake to liver 
was ,0.001%.
As systemic bioavailability differs among exposure 
routes, we normalized the time courses of concentration in 
tissues to that in liver. A comparison of the time courses to the 
blood:liver, spleen:liver, and brain:liver concentration ratios 
suggest several orders of magnitude of differences, between 
and among the IV, inhalation, IT instillation, and oral routes 
(Figures S13–S15). The time courses of the tissue:liver con-
centration ratios differ not only among exposure routes and 
studies but also between tissues (Figures S13–S15).
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Figure 4 sensitivity analyses of the physiologically based pharmacokinetic (PBPK) model calibrated with 5 and 30 nm ceria administered intravenously to rats. 
Notes: Normalized sensitivity coefficients for nanoparticle-specific parameters in blood, liver, spleen, brain, and phagocytic cell compartments are given for 10 h after dosing 
and at the end of the experiment (30 d for 5 nm and 90 d for 30 nm). experimental data used for modeling are from Yokel et al.15,60,61
Abbreviations: clf, clearance rate constant to feces; clu, clearance rate constant to urine; kab0, uptake rate constant by phagocytic cells; ksab0, uptake rate constant by 
phagocytic cells in spleen; kde, exocytosis rate constant from phagocytic cells; Mcap, maximum uptake capacity per phagocytic cell; P, partition coefficient between blood and 
tissue; Xfast, coefficient of permeability from blood to liver, spleen, and bone marrow; Xrest, coefficient of permeability from blood to lung, kidney, heart, and carcass; Xbrain, 
coefficient of permeability from blood to brain.
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Figure 5 Dose-dependent sensitivity analyses of the physiologically based pharmacokinetic (PBPK) model calibrated with 5 and 30 nm ceria administered intravenously into rats.
Notes: Calculation of normalized sensitivity coefficients for dose when nanoceria is infused intravenously at a dose rate ranging from 10 to 90 mg/kg/h over 1 h. Normalized 
sensitivity coefficients for dose in tissues, 10 h after a dose of 5 nm ceria (A) and 30 nm ceria (B). Data for A and B from Yokel et al.15,61 Normalized sensitivity coefficients 
for dose in liver, 10 h after dosing and at end of experiment (C).
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oral dosing where, with few exceptions, the concentrations 
in brain are in the same range as, or up to 1 order of magni-
tude lower than, in the liver. Finally, this suggests that the 
exposure route has a large influence on the biokinetics.
The first calibration efforts with inhalation, IT instillation, 
and oral data were unsuccessful, in that the model parameters 
could not be estimated. In a second attempt, calibrations 
were performed by adjusting the route-specific parameters 
only and keeping all other model parameters from the 5 and 
30 nm calibrations. With the second approach, the calibra-
tion was still unsuccessful for data set 1 from Li et al.49 
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Figure 6 calibration of physiologically based pharmacokinetic (PBPK) model of 30 nm ceria administered intravenously into rats. 
Notes: (A–E) simulated (solid curves) and observed (symbols) time courses of the 30 nm ceria concentration in different tissues and accumulated mass in urine and feces 
following 1 h infusion of 85 mg/kg body weight. Data for A–E from Yokel et al.15 (F) comparison of logs of simulated and observed mean concentration in different tissues 
and mean mass accumulated in urine and feces. The line of unity (solid) represents a perfect match, and the regression line (R2, dashed) describes the outcome.
In spite of differences in size and coatings, the time 
courses of the ratios after IV administration differed distinctly 
from the ratios for other exposure routes, illustrated, for 
example, by the clearly lower blood:liver concentration ratios 
and the apparently higher spleen:liver concentration ratios 
(Figures S13–S15). Noticeably and expected, the concentra-
tion in brain was substantially lower than in liver after IV 
administration (3–5 orders of magnitude) and IT instillation 
(2–4 orders of magnitude) compared to inhalation exposure 
(0–2 order of magnitude), suggesting uptake via olfactory 
nerves (Figure S15). This contrasts to the distribution after 
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No calibration of the Kumari et al study was carried out 
as these data were considered uncertain due to the small 
amounts recovered in feces and analyzed organs, appar-
ently ,10% of the administered dose (Figure S16).70 With 
few exceptions, poor fits were achieved for the remaining 
data sets (Figures S17–S23).17,49,67,69,70
Discussion
The PBPK model described herein is the first to describe 
the biokinetics of nanoceria injected IV in rats. In line with 
previous studies, our simulations give additional support 
that both properties of nanoparticles (size and coating) and 
exposure conditions (dose and route) affect the biokinetics 
of nanoceria.53,60 It should be noted that there are data avail-
able on experimental biokinetics of nanoceria in mice.72–74 
However, rats and mice differ substantially, especially with 
respect to the anatomy of the spleen and the properties of the 
MPS, which requires modification of the model.75–77
In a unique attempt to compare different exposure routes 
using PBPK modeling, the model structure was modified to 
include inhalation, instillation, and oral administration. How-
ever, modeling of these routes was difficult, and the results 
were inconclusive. We did not include intraperitoneal expo-
sure as this route is not relevant for environmental exposure 
or pharmacological treatment. Moreover, when we carried 
out a literature search on IP administration, we did not find 
any suitable biodistribution data for PBPK modeling.
The model adequately predicts the biokinetics of 5 nm 
ceria with citrate coating given IV to rats. The model is less 
successful in capturing the kinetics of other sizes of nano-
ceria, which partly can be explained by the larger spread in 
properties among these particles. Size-dependent uptake of 
nanoparticles in PCs has been reported by several research 
groups, and the optimum uptake by cells seems to occur for 
sizes around 40–60 nm.78,79 However, several other factors 
may also affect the uptake and excretion, such as cell type, 
nanoparticle–membrane binding energy, nanoparticle curva-
ture, and corona composition.80–83 In our simulations, some 
of the fitted parameters differed between 5 and 30 nm ceria 
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Figure 7 Validation of the physiologically based pharmacokinetic (PBPK) model 
against independent data sets with 30 nm ceria administered intravenously into rats.
Notes: comparison of logs of simulated and observed mean concentration 
in different tissues. The line of unity (solid) represents a perfect match, and the 
regression line (R2, dashed) describes the outcome. Different shapes/symbols 
represent different data sets and colors symbolize organs. Data from Konduru 
et al,53 Yokel et al,60,61,66 and Dan et al.65
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Figure 8 Uptake ratio of nanoceria to liver from different exposure routes.
Notes: Translocation of nanoceria from lung and gastrointestinal tract was 
calculated by dividing the cerium mass in liver with the administered dose, expressed 
as mass, that is, the uptake ratio. For inhalation, the cerium lung burden was used as 
the dose. For intravenous (IV) administration, the uptake ratio was calculated as the 
mass in liver divided by the administered dose. The symbols represent different data 
sets, and the colors represent different organs.
Table 5 Nanoparticle-dependent parameters of 5 and 30 nm 
ceria physiologically based pharmacokinetic (PBPK) model
Parametera Unit 30 nm 5 nm
Mean SD Mean SD
clf ml/h 3.92×10-2 7.25×10-5 a a
clu ml/h 7.15×10-5 1.41×10-7 a a
kde 1/h 2.88×10-3 6.76×10-6 1.42×10-3 2.29×10-6
kab0 1/h 2.68 3.66×10-3 5.13 2.37×10-3
ksab0 1/h 1.69×10-1 3.93×10-2 3.76 1.06×10-2
Mcap µg 3.98×10-5 8.28×10-8 3.43×10-5 7.22×10-8
P Unitless 8.85×10-2 1.67×10-4 0.40 9.23×10-4
Xbrain Unitless 2.90×10-8 3.72×10-11 7.02×10-6 8.33×10-9
Xfast Unitless 1.00 2.02×10-3 0.59 5.22×10-3
Xrest Unitless 1.86×10-4 2.60×10-7 1.51×10-3 2.91×10-6
Notes: aFixed value, same as for 30 nm ceria.
Abbrevations: clf, clearance rate constant to feces; clu, clearance rate constant 
to urine; kab0, uptake rate constant by phagocytic cells; ksab0, uptake rate constant 
by phagocytic cells in spleen; kde, exocytosis rate constant from phagocytic cells; 
Mcap, maximum uptake capacity per phagocytic cell; P, partition coefficient between 
blood and tissue; Xfast, coefficient of permeability from blood to liver, spleen, and 
bone marrow; Xrest, coefficient of permeability from blood to lung, kidney, heart, and 
carcass; Xbrain, coefficient of permeability from blood to brain.
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suggesting size dependencies, whereas other parameters were 
similar for the two nanoceria sizes. Overall, our modeling 
results point to dependence not only on size but also on 
coating, dose, and exposure route on the biokinetics.
Coating is a known modifying factor of biokinetics 
for nanoparticles, including nanoceria.53,58,62 According to 
Heckman et al, the clearance of nanoceria from blood is 
reduced when EDTA is added to the citrate coating.62 Our 
model is well in line with this finding as our model, calibrated 
with citrate-coated 5 nm ceria, predicts a faster clearance than 
observed in experimental data with citrate/EDTA-coated 
3 nm ceria.62 Heckman et al argued that the prolonged blood 
circulation time observed for citrate/EDTA-coated nanoceria 
compared to citrate-coated nanoceria may be explained by 
fewer adsorbed proteins, resulting in reduced recognition and 
uptake by the mononuclear phagocytic system.62 Similarly, 
Konduru et al proposed that the alteration in biodistribu-
tion patterns between uncoated and silica-coated nanoceria 
correlates with differences in the corona composition.53
Our PBPK model includes saturable uptake of nanoceria 
in PCs as a major feature. At sufficiently high doses, tissue 
levels will be less than proportional to dose as the PCs 
approach saturation. Moreover, PCs are unevenly distributed 
among tissues and permeability into tissues varies, as high, 
medium, or low (X
brain
, X
fast
, and X
rest
). Therefore, the nano-
ceria distribution pattern will change as the dose increases. 
To develop reliable and validated PBPK models, one would 
need to validate them against low (non-saturating) as well 
as high (saturating) doses. Unfortunately, nearly all experi-
mental studies that could be used for modeling used a single 
dose only, or a very narrow dose span (Tables 1–4).
Our model was not designed to, and cannot, account for 
the peculiar biokinetic behavior seen in one of Yokel et al 
studies, where the concentration increased up to three orders 
of magnitude in various tissues between 1 and 3 months 
after IV infusion of 30 nm ceria (Figure 6).15 One possible 
explanation might be the dissolution of nanoceria in the liver 
and subsequent release of cerium ion, resulting in increased 
cerium in the blood and redistribution to the spleen.71,84 On the 
other hand, the observed biokinetic pattern is not consistent 
with that reported for cerium ion.14 If this peculiar increase 
is indeed a true biokinetic phenomenon, better understanding 
of the underlying physical or physiological mechanisms is 
needed in order to further develop the PBPK model. In addi-
tion, improved quantitative analytical methods that are able 
to distinguish between primary and secondary cerium oxide 
nanoparticles and cerium ions would be needed.
When comparing the experimental data for different 
exposure routes, it quickly became apparent that the present 
PBPK model is unable to describe the biokinetics for the 
non-IV routes. This was later confirmed during our modeling 
efforts. However, our comparison of the experimental data for 
IV, inhalation, instillation, and oral exposure suggests that the 
tissue distribution pattern is a result of the need for nanoceria 
to cross epithelial barriers before reaching the systemic circula-
tion (see Figures S13–S15 for time course plots of tissue:liver 
concentration ratios for the different exposure routes). Modifi-
cation of biodistribution as a result of exposure route has also 
been demonstrated for other types of nanoparticles such as 
gold.85,86 These pattern changes may be due to a “true” route 
dependency, but may also reflect differences in nanoparticle 
property, dose, tissue sampling techniques, sample treatment, 
analytical method, and so on among the studies. The underly-
ing mechanisms are unclear; however, modified protein bind-
ing has been suggested as a likely factor.86 Additional studies 
are needed to understand the possible route dependency and 
to rule out other experiment-related factors.
Development, calibration, and validation of PBPK models 
for nanoparticles require reliable and relevant experimental 
data that provide information about properties of nanopar-
ticles as well as quantities in several tissues at multiple time 
points over extended periods. Among all published reports 
on nanoceria, only a few data sets comprised this type of 
information. Small sample size in combination with high 
intra- and inter-individual variability and method error are 
other complication factors for modeling as these lower the 
confidence in the parameter estimates as well as the model 
structure. An additional problem with the non-IV exposure 
routes is that absorption is generally low, resulting in very 
low tissue levels, sometimes below the detection limit and/or 
not different from background.
In the data sets provided by Yokel et al, we had access 
to raw data, and hence individual data on body weight and 
tissue weights could be used in the model.15,60,61,63,65,66 Infor-
mation for the other data sets are more uncertain as they 
were reported as mean values. The latter situation typically 
reflects how data are reported in published biodistribution 
studies where individual data points are rarely provided. 
More frequent reporting of individual data would be helpful 
to improve model development and to facilitate discrimina-
tion between variability and uncertainty.
Due to lack of quantitative physiological knowledge, 
several of the PBPK parameters had to be fitted to experi-
mental data. Such approaches may result in over parameter-
ization, especially if the experimental data are limited to a few 
tissues and time points. In this study, 10 parameters were opti-
mized and 156 data points were used to calibrate the model. 
Noteworthily, the number of data points were well above 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
16
3.
8.
74
 o
n 
09
-J
an
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2643
PBPK modeling of nanoceria suggests dose- and route-dependent biokinetics
the number of parameters optimized which reduces the risk 
for over fitting. In addition, the model has successfully been 
used to describe the biokinetics of other nanoparticles (tita-
nium dioxide, gold, and polyethylene-coated and -uncoated 
polyacryl amide) administered IV.38,52
A parameter with a high sensitivity coefficient means that 
a small change in this parameter will have a high impact on 
the model output. Reliable experimental data on these param-
eters are hence critical. On the other hand, a parameter with 
very low sensitivity can have a range of values with negligible 
impact on the output. Model estimates of such parameters are 
thus more uncertain. Overall, the sensitivity analysis showed 
time, dose, and size dependencies (Figure 4, Tables S2–S7). 
The model parameters were generally more sensitive for the 
5 nm than 30 nm ceria, and in addition, the sensitivity of the 
parameters increased with dose. The dose-dependent increase 
in sensitivity can be explained by increased nanoceria burden 
in the PCs, expressed as higher sensitivity coefficients for 
such parameters as the maximum uptake capacity per PC 
(M
cap
), number of PCs per gram liver (n
cap
 
in
 
liver
), and liver 
fraction of body weight (k
wl
) (Tables S2–S7).
Experimental values for physiologically based parameters 
can be found in the literature, and many of them can also be 
readily measured.87,88 However, reliable data on, for example, 
residual amount of blood in tissues and number of PCs in 
tissues are sparse. Relevant and reliable experimental data 
on nanoparticle-dependent parameters are more difficult to 
find. Methods, primarily in vitro, are under development, but 
the result will depend on the properties of the nanoparticles 
and the test method used.46,89–91 Correlations between in vitro 
and in vivo results need to be established to make route-to-
route extrapolations.92 Consequently, it is difficult, at least 
so far, to predict how properties of nanoparticles may affect 
the parameters of the PBPK model.
The biological environments in the gastrointestinal tract 
and the lungs differ from that in blood, and this may affect 
the behavior of the nanoparticles with respect to processes 
such as agglomeration, corona formation, and nanoparticle 
dissolution.57,93–95 These processes depend not only on the 
environment but also on the properties of nanoparticles and 
contribute to changes in the biodistribution pattern.54,81,96 
There are also indications that the processes are dynamic and 
change over time.54,97,98 Hence, an obvious next step would 
be to examine if introduction of these processes in the PBPK 
model improves the predictions. To our knowledge, there is 
no PBPK model for nanoparticles with physically relevant 
descriptions of agglomeration, corona formation, and dis-
solution, although dissolution has been empirically imple-
mented in PBPK models for silver and zinc.35,45 A limiting 
factor is that the three processes have so far not been well 
characterized in quantitative terms, and consequently, they 
cannot yet be used in PBPK modeling.54
Our model has a simplified structure that describes 
the deposition and transport processes in the lung and 
gastrointestinal tract. Research groups have shown that a 
more complex model structure for deposition and clear-
ance in the respiratory system via mucociliary clearance to 
pharynx and uptake to brain via olfactory and trigeminal 
nerves is more adequate to predict the deposition of inhaled 
nanoparticles.47,49 Systemic uptake of nanoparticles via the 
lymphatic system and subsequent distribution to tissues has 
been demonstrated but so far not incorporated in any PBPK 
model for nanoparticles.99,100 This can be explained by the 
challenge in visualization and sampling of lymph nodes 
and the small amounts of nanoparticles therein; thus, the 
observations are qualitative rather than quantitative. Even 
if incorporated, the model would still not be able to explain 
the route-dependent biodistribution patterns.
Our study illustrates well the usefulness of PBPK mod-
eling to better understand the biokinetics of nanoparticles. 
First, PBPK modeling can be used to challenge or generate 
hypotheses. Thus, the PBPK model described herein supports 
the hypothesis that coating and size influence biokinetics. 
Second, PBPK models can be used to identify knowledge 
gaps. In this study, we identified the need to update future 
models with mechanistic understanding of exposure route 
dependencies and nanoparticle interactions with body fluids 
such as corona formation, agglomeration, and dissolution. 
Third, PBPK models may be used to improve the design of 
experimental studies. Our modeling efforts suggest dose- and 
route-dependent biokinetics of nanoceria. Hopefully this will 
be taken into consideration when future biodistribution stud-
ies are designed. Fourth, PBPK models can be used to predict 
the biokinetics and tissue doses for new exposure scenarios 
without need for new experiments. This is particularly impor-
tant in risk assessment of nanoparticles when there seems to 
be dose- or route-dependent biokinetics.
Conclusion
The PBPK model could adequately describe and predict 
the biokinetics for 5 nm ceria with citrate coating given 
IV but less well so for other sizes. For non-IV exposure 
routes, calibration was difficult due to low absorption, few 
samples, widely disparate data, and concentrations below 
or close to the detection limit. However, the tissue time 
courses seemed to differ from those in the IV experiments 
and had shapes that were difficult to reproduce with the 
PBPK model. Overall, our modeling results suggest that the 
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biokinetics of nanoceria depend not only on the properties 
of nanoparticles (size and coating) but also, and even more 
so, on the exposure conditions (route and dose). Inclusion of 
physically and physiologically adequate descriptions of lung 
deposition, agglomeration, corona formation, and dissolution 
is needed. This requires improved mechanistic understanding 
and targeted experimental studies.
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